Sandoz creates biosimilar unit to benefit from major patent cliff
Source: SeekingAlpha
2026-03-10 11:59:24 ET
More on Sandoz Group AG
- Sandoz Group AG 2025 Q4 - Results - Earnings Call Presentation
- Sandoz Group AG (SDZNY) Q4 2025 Earnings Call Transcript
- Sandoz: The Share Price May Have Run Its Course
- Sandoz Group AG Non-GAAP EPS of $3.64 beats by $0.38, revenue of $11.1B beats by $20M
- Sandoz wins FDA nod to expand Enzeevu label to multiple retinal indications
Read the full article on Seeking Alpha
For further details see:
Sandoz creates biosimilar unit to benefit from major patent cliff
Sandoz Group AG
NASDAQ: SDZNY
SDZNY Trading
-5.16% G/L:
$78.566 Last:
66,967 Volume:
$80 Open:
SDZNY Latest News
September 24, 2025 04:15:00 pm
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
August 27, 2025 07:30:00 am
Sandoz welcomes Quebec government support for Boucherville plant modernization project
August 12, 2025 01:00:00 am
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
August 07, 2025 01:00:00 am
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
